Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
A shareholder of BLLN, identified as David Tsao, has filed a notice of intent to sell 10,000 Class A shares through Fidelity Brokerage Services on NASDAQ, with an indicated value of $928,600.00 as of August 10, 2026.
The filing also reports prior sales of 20,000 Class A shares for $2,045,326.00 on June 15, 2026 and another 20,000 shares for $2,497,698.00 on July 13, 2026. The upcoming sale is associated with a stock option exercise to be settled in cash.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan exercised stock options to acquire 15,539 shares of Class A Common Stock at $2.80 per share, then sold 15,539 shares at a weighted average of $150.0323 per share. The options were fully vested and exercisable, leaving 526,961 stock options outstanding. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan reported multiple equity transactions in Class A Common Stock. On August 3, 2026 he exercised stock options to acquire 32,500 shares at $2.80 per share from fully vested awards expiring 2031-06-07, and reported sales totaling 45,000 shares in numerous trades at weighted average prices between $132.500 and $139.500 per share, including shares held by his spouse. All transactions were effected under a Rule 10b5-1 trading plan adopted March 6, 2026.
Affiliated shareholders of BLLN filed a Form 144 to sell up to 15,539 Class A shares through a stock option exercise for cash, with the proposed sale dated 08/05/2026. The filing lists an aggregate market value of $2,331,352.23 for these shares and notes 41,442,834 Class A shares outstanding as of 08/05/2026; this is a baseline figure, not the amount being offered.
Over the prior three months, the filing reports multiple Class A share sales by Oguzhan Atay, Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust on 06/08/2026, 07/06/2026, 07/09/2026, and 08/03/2026, each with specified share amounts and dollar proceeds.
BillionToOne, Inc. reported Q2 2026 results with revenue of $109,448 thousand versus $66,573 thousand a year earlier and net income of $8,054 thousand compared with a loss of $246 thousand. For the six months ended June 30, 2026, revenue was $217,836 thousand and net income was $26,024 thousand, with diluted EPS of $0.48.
Cash and cash equivalents totaled $548,628 thousand at June 30, 2026 against long‑term debt of $91,031 thousand. The company processed approximately 197,000 billable tests in Q2, up from 148,000, and highlights growth in prenatal UNITY and Northstar oncology testing, expanded payor agreements, AI‑enabled reimbursement operations, and major planned expansions in laboratory capacity and oncology offerings.
BillionToOne, Inc. reported second-quarter 2026 results with total revenue of $109.4 million, up 64% from $66.6 million a year earlier, driven by 196,000 tests delivered and a 21% increase in overall average selling price.
Prenatal testing revenue was $94.2 million and oncology testing revenue $13.7 million, up 55% and 176% year-over-year, respectively. Gross margin improved to 70% from 65%, with income from operations of $5.5 million and net income of $8.1 million, or $0.15 per diluted share. Free cash flow was $5.1 million, and cash and cash equivalents were $548,628 (in thousands) as of June 30, 2026.
The company reaffirmed 2026 revenue guidance of $450.0 million to $465.0 million, representing 48% to 52% growth over 2025, and expects to generate profitability similar to current levels while continuing to invest. Product updates include a 130-gene Unity Fetal Risk Screen panel and the Northstar Origin tissue-of-origin feature, with commercial availability beginning in August and September 2026.
BillionToOne, Inc. Chief Product Officer Sakakibara Shan Riku sold 4,000 shares of Class A Common Stock on July 31, 2026 at $140.21 per share. Following this open-market sale, the executive directly holds 200,000 shares, with the transaction effected under a Rule 10b5-1 trading plan adopted March 6, 2026.
BLLN filed a notice of proposed sale under Rule 144 for 2,500 Class A shares held at Fidelity Brokerage Services LLC. The shares were originally acquired as Pre-IPO Shares for cash on 12/30/2021 and are planned to be sold on 08/03/2026 on NASDAQ for an aggregate value of $343,425.00. The filing also lists multiple prior Class A share sales over the past three months by Oguzhan Atay, Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust.
The BLLN issuer filed to potentially sell 12,500 Class A shares, to be executed through Fidelity Brokerage Services LLC, with an aggregate value of $1,717,125.00 and a noted date of August 3, 2026. These are described as Pre-IPO Shares to be sold for cash.
The filing also lists Class A share sales during the prior three months by related holders Oguzhan Atay, Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust on June 8, 2026, July 6, 2026, and July 9, 2026, with individual transaction sizes ranging from 2,500 to 26,250 shares and corresponding aggregate sale prices disclosed for each trade.
BLLN has a notice to sell up to 32,500 Class A shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ on August 3, 2026, in connection with a stock option exercise. The proposed sale amount is listed at an aggregate value of $4,488,575.00.
The filing also lists Class A share sales during the prior three months by Oguzhan Atay, Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust. These include 26,250 shares on June 8, 2026 for $2,563,632.00, 26,250 shares on July 6, 2026 for $3,203,733.13, and 12,500 shares on July 9, 2026 for $1,576,276.25, along with additional transactions by related holders.